The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Celldex Therapeutics Inc (NASDAQ: CLDX) was $26.53 for the day, down -3.88% from the previous closing price of $27.60. In other words, the price has decreased by -$3.88 from its previous closing price. On the day, 1.94 million shares were traded. CLDX stock price reached its highest trading level at $29.04 during the session, while it also had its lowest trading level at $25.81.
Ratios:
Our analysis of CLDX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 24.27 and its Current Ratio is at 24.27. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on October 07, 2024, initiated with a Buy rating and assigned the stock a target price of $70.
On September 30, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $45.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 11 ’24 when Marucci Anthony S bought 11,500 shares for $26.82 per share. The transaction valued at 308,430 led to the insider holds 40,284 shares of the business.
Martin Samuel Bates sold 17,172 shares of CLDX for $608,315 on Jun 14 ’24. The SVP AND CFO now owns 28,125 shares after completing the transaction at $35.42 per share. On Jun 14 ’24, another insider, Crowley Elizabeth, who serves as the SR. VP & CPDO of the company, sold 30,000 shares for $34.87 each. As a result, the insider received 1,045,962 and left with 9,074 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 1760111616 and an Enterprise Value of 1007200576. For the stock, the TTM Price-to-Sale (P/S) ratio is 176.36 while its Price-to-Book (P/B) ratio in mrq is 2.24. Its current Enterprise Value per Revenue stands at 100.962 whereas that against EBITDA is -5.888.
Stock Price History:
Over the past 52 weeks, CLDX has reached a high of $53.18, while it has fallen to a 52-week low of $22.93. The 50-Day Moving Average of the stock is 1.38%, while the 200-Day Moving Average is calculated to be -22.59%.
Shares Statistics:
CLDX traded an average of 989.05K shares per day over the past three months and 917090 shares per day over the past ten days. A total of 66.34M shares are outstanding, with a floating share count of 64.70M. Insiders hold about 2.48% of the company’s shares, while institutions hold 107.05% stake in the company. Shares short for CLDX as of 1734048000 were 7308344 with a Short Ratio of 7.39, compared to 1731628800 on 7834833. Therefore, it implies a Short% of Shares Outstanding of 7308344 and a Short% of Float of 12.740000000000002.
